Navigation Links
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
Date:8/24/2011

SAN DIEGO, Aug. 24, 2011 /PRNewswire/ -- Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, and Clarient, Inc. (a GE Healthcare Company) today announced a collaboration on the commercialization of a proprietary blood test for CTCs in breast cancer patients, which includes the determination of HER2 status.  Clarient and Biocept will market and sell Biocept's new OncoCEE-BR™ CTC test to community hospitals, pathologists and medical oncologists.  Biocept will perform the test in its laboratories, and results will be interpreted by Clarient's highly respected pathology group (Clarient Pathology Services, Inc.).   The test includes CTC enumeration and HER2 status of the detected CTCs by fluorescence in situ hybridization (FISH); it is the first commercially available CTC test to include analysis of a specific treatment-associated biomarker.  

David Hale, Executive Chairman of Biocept, said, "We are very excited about this collaboration with Clarient, and feel there is real synergy between our two companies.  We believe the combination of the technical advantages of the OncoCEE-BR™ test, and Clarient's highly regarded marketing and pathology capabilities, will enable the rapid education of the physician community about the benefits of CTC analysis for patients with breast cancer."  He continued, "We think a blood-based, CTC-directed HER2 test, which can be performed when a treatment decision arises, has high potential, and expect that it will be used to support other laboratory and clinical information to provide physicians with the most current information on a tumor to help select the most appropriate course of therapy."

The OncoCEE-BR™ test includes enumeration of CTCs as well as the determination of HER2 status by FISH.  Biocept intends to add ER/PR status determination to the test, an
'/>"/>

SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biocept, Inc. Announces CEO and Director Appointments
2. Biocept, Inc. Announces Two New Director Appointments
3. Biocept, Inc. Announces New Director Appointment - September 28, 2010
4. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
5. Biocept, Inc. Announces New CFO
6. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BRâ„¢ Utilizing Circulating Tumor Cells (CTCs)
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
10. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
11. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for its Oral Amphotericin B program.  The company ... vitro work involving samples from HIV/AIDS patients ... complete pre clinical studies and regulatory filings to ... trial, utilizing approximately $700,000 of funding and technological ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/19/2014)... 19, 2014 The Latin American hardware ... in Latin America with analysis and forecast of revenue. ... and is expected to reach $2,366.8 million by 2018, ... , Browse through the TOC of the Latin American ... the in-depth analysis provided. It also provides a glimpse ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... , , OMAHA, Neb., Dec. 8 ... of its SURVEYOR Scan K-RAS kit, the first in a ... featuring its proprietary SURVEYOR Nuclease and WAVE ® HS ... to mutation detection that uses a PCR amplification reaction and ...
... , NEW YORK, Dec. 8 Reportlinker.com ... in its catalogue: , Microplate Instrumentation & ... http://www.reportlinker.com/p0164370/Microplate-Instrumentation--Supplies---A-Global-Market-Perspective.html , Playing a pivotal role in ... has come to replace conventional micro test tubes and ...
... ... , AMSTERDAM, December 8 , ... , Elsevier, a world-leading publisher of scientific, technical ... new SciVal Spotlight tool. The institutions, including,National Chiao Tung University (Taiwan), St. ...
Cached Biology Technology:Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 2Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 3Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 4Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 5Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 6Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 7Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 8SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/16/2014)... 16, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... including Wocket™, the Smart Wallet, at the 13 th ... a leading global conference on the intersection of technology ... Mark Anderson , founder and publisher of the Strategic ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Might those bacteria lead oil companies to change their methods ... same time reducing the carbon dioxide that burning oil and ... be possible. Larter, professor of geoscience and holder ... University of Calgary, was the keynote speaker today for the ...
... a firm link between environmental change and human disease ... a team of scientists from the University of Wisconsin-Madison, ... of the CDC journal Emerging Infectious Diseases, ... incidence of malaria to land-use practices in the Amazon. ...
... bacteria in seven species of sharks and redfish captured ... of these wild, free-swimming fish harbored several drug-resistant bacterial ... Journal of Zoo and Wildlife Medicine , found antibiotic-resistant ... also found multidrug-resistant bacteria in fish at nearly all ...
Cached Biology News:Incidence of malaria jumps when Amazon forests are cut 2Incidence of malaria jumps when Amazon forests are cut 3Wild sharks, redfish harbor antibiotic-resistant bacteria 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Assay Diluent 500 mls...
ICC Diluent Buffer 250 ml...
...
Biology Products: